Literature DB >> 6129301

Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood.

M Lemaire, J P Tillement.   

Abstract

The distribution of cyclosporin A between plasma, leucocytes and erythrocytes was studied in vitro by means of sedimentation in Ficoll-Paque and dextran. The uptake by erythrocytes was found to be about 50% and the fraction of cyclosporin A bound to leucocytes amounted to 15%. Fractionation of plasma by ultracentrifugation also showed that two thirds of the drug were associated with lipoproteins whereas binding studies with isolated lipoproteins and plasma also indicated that lipoproteins were the major complexing constituents for cyclosporin A in plasma. The binding of cyclosporin A to erythrocytes and lipoproteins seems to be a linear process. The binding to the leucocytes may be a saturable process, however it is of minor importance in terms of the overall binding capacity in the blood.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6129301     DOI: 10.1111/j.2042-7158.1982.tb06206.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  53 in total

1.  Binding of propofol to blood components.

Authors:  E Suarez; R Calvo; M K Zamacona; J Lukas
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

Review 2.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  Influence of dyslipidemia on moxidectin distribution in plasma lipoproteins and on its pharmacokinetics.

Authors:  Mohamad Firas Bassissi; Michel Alvinerie; Pascal Guy Pierre Martin; Bertrand Perret; Anne Lespine
Journal:  Pharm Res       Date:  2006-09-15       Impact factor: 4.200

Review 4.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 5.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

6.  Clinical pharmacokinetics of ciclosporin A in bone marrow transplantation patients.

Authors:  P Bertault-Pérès; D Maraninchi; Y Carcassonne; J P Cano; J Barbet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  A low density lipoprotein-methotrexate covalent complex and its activity against L1210 cells in vitro.

Authors:  G W Halbert; J F Stuart; A T Florence
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 8.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Cyclosporine pharmacokinetic profiles in liver, heart, and kidney transplant patients as determined by high-performance liquid chromatography.

Authors:  G J Burckart; R Venkataramanan; R J Ptachcinski; T E Starzl; B P Griffith; T R Hakala; J T Rosenthal; R L Hardesty; S Iwatsuki; J Brady
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

10.  Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment.

Authors:  Ric M Procyshyn; Kishor M Wasan; Allen E Thornton; Alasdair M Barr; Eric Y H Chen; Edith Pomarol-Clotet; Emmanuel Stip; Richard Williams; G William Macewan; C Laird Birmingham; William G Honer
Journal:  J Psychiatry Neurosci       Date:  2007-09       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.